Shandong Sito Bio-technology announced that its holding subsidiary, ShanDong SuiRui Pharmaceutical Co., Ltd., recently received the approval notice for the marketing application of triamcinolone issued by the National Medical Products Administration. Triamcinolone is a corticosteroid that can be used topically to treat dermatoses, eczema, and other skin infectious diseases. It can also be used for the treatment of diseases requiring corticosteroids through intramuscular injection.
赛托生物：子公司收到曲安奈德化学原料药上市申请批准通知书
Shandong Sito Bio-technology: The subsidiary has received the approval notice for the marketing application of triamcinolone Chemical Raw Materials.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated